Skip to content
Subscriber Only

Roche Drops After Halting Cholesterol Drug Development

Roche Holding AG fell the most in almost six months in Zurich trading after abandoning development of an experimental cholesterol drug as a late-stage trial showed it wasn’t working.

An independent group of experts recommended stopping the study of dalcetrapib “due to a lack of clinically meaningful efficacy,” Basel, Switzerland-based Roche said in a statement today. The company had planned a six-trial development program that could have put more than 35,000 patients on the drug, intended to boost so-called good cholesterol.